bioAffinity Technologies, Inc. (BIAFW)

NASDAQ: BIAFW · Real-Time Price · USD · Warrants
0.1451
+0.0051 (3.64%)
Jun 6, 2025, 11:47 AM - Market open
3.64%
Market Cap 7.75M
Revenue (ttm) 8.81M
Net Income (ttm) -9.74M
Shares Out 26.82M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 634
Open 0.1451
Previous Close 0.1400
Day's Range 0.1451 - 0.1451
52-Week Range 0.1020 - 2.9000
Beta 3.03
Analysts n/a
Price Target n/a
Earnings Date Mar 28, 2025

About BIAFW

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have... [Read more]

Sector Healthcare
Founded 2014
Employees 57
Stock Exchange NASDAQ
Ticker Symbol BIAFW
Full Company Profile

Financial Performance

In 2024, bioAffinity Technologies's revenue was $9.36 million, an increase of 269.68% compared to the previous year's $2.53 million. Losses were -$9.04 million, 13.9% more than in 2023.

News

There is no news available yet.